Successful rechallenge with cisplatin following cisplatin induced ischemic cerebrovascular accident in a patient with small cell lung cancer

Farah Rashid; Nabil E Omar; Hassan Aaekl; Ussama Al Homsi; Alaaeldin Shablak

doi:10.1002/ccr3.6469

Successful rechallenge with cisplatin following cisplatin induced ischemic cerebrovascular accident in a patient with small cell lung cancer

Clin Case Rep. 2022 Oct 20;10(10):e6469. doi: 10.1002/ccr3.6469. eCollection 2022 Oct.

Authors

Farah Rashid¹, Nabil E Omar², Hassan Aaekl³, Ussama Al Homsi³, Alaaeldin Shablak³

Affiliations

¹ Department of Internal Medicine Hamad General Hospital, Hamad Medical Corporation Doha Qatar.
² Pharmacy Department National Center for Cancer Care and Research, Hamad Medical Corporation Doha Qatar.
³ Department of Medical Oncology National Center for Cancer Care and Research, Hamad Medical Corporation Doha Qatar.

Abstract

Cisplatin is a widely used platinum-based chemotherapy agent. Its common adverse effects are neuropathy, nephrotoxicity, electrolyte abnormality, and rarely causing thrombotic vascular toxicity. We present a patient known to have small-cell lung cancer who developed ischemic cerebrovascular accident (CVA) after receiving chemotherapy regimen including cisplatin.

Keywords: cerebrovascular accident; cisplatin; cisplatin induced stroke; small cell lung cancer.

Publication types

Case Reports